Prenatal education for congenital toxoplasmosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Di Mario, Simona ^a   Basevi, Vittorio ^a   Gagliotti, Carlo ^b   Spettoli, Daniela ^a   Gori, Gianfranco ^a   D'Amico, Roberto ^c   Magrini, Nicola ^b  

^a Primary Care Physicians in Private Practice   (Italy)

^b Regional Agency for Health and Social Care   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY SPECIFICITY; ANTIBODY TITER; AWARENESS; BEHAVIOR CHANGE; CHILDBIRTH EDUCATION; CONGENITAL TOXOPLASMOSIS; DISEASE ASSOCIATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; NEWBORN SCREENING; OUTCOME ASSESSMENT; PRENATAL SCREENING; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY PREVENTION; SEROCONVERSION; SYSTEMATIC REVIEW; EDUCATION; FEMALE; HYGIENE; METHODOLOGY; PARASITOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL CARE; RARE DISEASE;

FEMALE; HUMANS; HYGIENE; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RARE DISEASES; TOXOPLASMOSIS, CONGENITAL;

EID: 84875502833     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006171.pub3     Document Type: Review

References (50)

1. Carter AO, Gelmon SB, Wells GA, Toepell AP. The effectiveness of a prenatal education programme for the prevention of congenital toxoplasmosis. Epidemiology and Infection 1989;103:539-45.
2. Gollub EL, Leroy V, Gilbert R, Chêne G, Wallon M, the European Toxoprevention Study Group (EUROTOXO). Effectiveness of health education on Toxoplasma-related knowledge, behaviour, and risk of seroconversion in pregnancy. European Journal of Obstetric & Gynecology and Reproductive Biology 2008;136:137-45.
3. Nguyen DT. Evolution des connaissances et des comportements au cours d'un programme d'éducation prénatal pour la prévention primaire de la toxoplasmose congénitale chez les femmes enceintes séronégatif pour la toxoplasmose. Règion de Lyon, 1994-1995 [Impact on knowledge and behaviour of a prenatal education programme to prevent congenital toxoplasmosis among seronegative pregnant women. Lyon region, 1994-1995] [Masters thesis]. Bordeaux: University of Bordeaux, Juillet 2004.
4. Wallon M, Nguyen Hoang Hanh DT, Peyron F, Chene G. Impact of health education for the primary prevention of toxoplasma infection in pregnancy: lessons from the ERIS study. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 2006 April 1-4; Nice, France. 2006:Abstract no: P876.
5. Breugelmans M, Naessens A, Foulon W. Prevention of toxoplasmosis during pregnancy - an epidemiologic survey over 22 consecutive years. Journal of Perinatal Medicine 2004;32:211-4.
6. Foulon W, Naessens A, Derde MP. Evaluation of the possibilities for preventing congenital toxoplasmosis. American Journal of Perinatology 1994;11:57-62.
7. Foulon W, Naessens A, Lauwers S, De Meuter F, Amy JJ. Impact of primary prevention on the incidence of toxoplasmosis during pregnancy. Obstetrics & Gynaecology 1988;72:363-6.
8. Molé JR, Suárez D, Alonso F, Piquera G. This is what we did to prevent congenital toxoplasmosis in Manzanillo [Lo que hacemos para prevenir la toxoplasmosis congénita en Manzanillo]. Revista Cubana de Medicina General Integral 1992;8(4):330-2.
9. Pawlowski ZS, Gromadecka-Sutkiewicz M, Skommer J, Paul M, Rokossowski H, Suchocka E, et al.Impact of health education on knowledge and prevention behavior for congenital tooplasmosis: the experience in Poznan, Poland. Health Education Research 2001;16(4):493-502.
10. Alfirevic Z, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD003252]
11. Allain JP, Palmer CR, Pearson G. Epidemiological study of latent and recent infection by toxoplasma gondii in pregnant women from a regional population in the UK. Journal of Infection 1998;36:189-96.
12. Bader TJ, Macones GA, Asch DA. Prenatal screening for toxoplasmosis. Obstetrics & Gynecology 1997;90:457-64.
13. Boyer KM, Holfels E, Roizen N, Swisher C, Mack D, Remington J, et al.Risk factors for toxoplasma gondii infection in mothers of infants with congenital toxoplasmosis: implications for prenatal management and screening. American Journal of Obstetrics and Gynecology 2005;192:564-71.
14. Campbell MK, Elbourne DR, Altman DG for the CONSORT Group. CONSORT statement: extension to cluster randomised trials. BMJ 2004;328:702-8.
15. Chabbert E, Lachaud L, Crobu L, Bastien P. Comparison of two widely used PCR primer systems for detection of toxoplasma in amniotic fluid, blood, and tissues. Clinical Microbiology 2004;42:1719-22.
16. Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA, et al.Sources of toxoplasma infection in pregnant women: European multicentre case-control study. European Research Network on Congenital Toxoplasmosis. BMJ 2000;321:142-7.
17. Dunn D. Mother to child transmission of toxoplasmosis: risks estimates or clinical counselling. Lancet 1999;353:1829-33.
18. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
19. Dean AG, Dean JA, Coulombier D, Brendel KA, Smith DC, Burton AH, et al.EpiInfo, Version 6: a word processing, database, and statistics programs for epidemiology on microcomputers. Atlanta: Centers for Disease Control and Prevention, 1994.
20. Ferguson W, Mayne PD, Cafferkey M, Butler K. Lack of awareness of risk factors for primary toxoplasmosis in pregnancy. Irish Journal of Medical Science 2011;180:807-11.
21. Foulon W, Naessens A, Lauwers S, De Meuter F, Amy JJ. Impact of primary prevention on the incidence of toxoplasmosis during pregnancy. Obstetrics & Gynecology 1988;72:363-6.
22. Foulon W, Naessens A, Derde MP. Evaluation of the possibilities for preventing congenital toxoplasmosis. American Journal of Perinatology 1994;11:57-62.
23. Foulon W, Villena I, Stray-Pederson B, Decoster A, Lappalainen M, Pinon JM, et al.Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children sequelae at age 1 year. American Journal of Obstetrics and Gynecology 1999;180:410-5.
24. Foulon W, Pinon JM, Stray-Pederson B, Pollak A, Lappalainen M, Decoster A, et al.Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. American Journal of Obstetrics and Gynecology 1999;181:843-7.
25. Gilbert RE. Epidemiology of infection in pregnant women. In: Petersen E, Amboise-Thomas P editor(s). Congenital Toxoplasmosis: Scientific Background, Clinical Management and Control. Paris: Springer-Verlag France, 1999.
26. Gilbert R, Dunn D, Wallon M, Hayde M, Prusa A, Lebech M, et al.Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiology and Infection 2001;127:113-20.
27. Gilbert RE, Peckham CS. Congenital toxoplasmosis in the United Kingdom: to screen or not to screen?. Journal of Medical Screening 2002;9:135-41.
28. Gilbert R, Gras L. European multicentre study on congenital toxoplasmosis. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG: an international journal of obstetrics and gynaecology 2003;110:112-20.
29. Gilbert RE, Thalib L, Tan HK, Paul M, Wallon M, Petersen E. Screening for congenital toxoplasmosis: accuracy of immunoglobulin M and immunoglobulin A tests after birth. Journal of Medical Screening 2007;14:8-13.
30. Hahn S, Puffer S, Torgerson DJ, Watson J. Methodological bias in cluster randomised trials. BMC Medical Research Methodology 2005;5:10.
31. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57.
32. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
33. Lebech M, Joynson DH, Seitz HM, Thulliez P, Gilbert RE, Dutton GN, et al.Classification system and case definitions of toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis. European Journal of Clinical Microbiology and Infectious Diseases 1996;15:799-805.
34. Lebech M, Andersen O, Christensen NC, Hertel J, Nielsen HE, Petersen B, et al.Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment. Danish Congenital Toxoplasmosis Study Group. Lancet 1999;353:1834-7.
35. Liesenfeld O, Press C, Montoya JG, Gill R, Isaac-Renton JL, Hedman K, et al.False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia toxo IgM test. Journal of Clinical Microbiology 1997;35:174-8.
36. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004;363:1965-76.
37. National Screening Committee Working Group. Antenatal and Newborn Screening for Toxoplasmosis. Report of the Working Group -- October 2001. National Screening Committee, 2001.
38. Peyron F, Wallon M, Liou C, Garner P. Treatments for toxoplasmosis in pregnancy. Cochrane Database of Systematic Reviews 1999, Issue 3. [DOI: 10.1002/14651858.CD001684]
39. Puffer S, Torgerson D, Watson J. Evidence for risk of bias in cluster randomised trials: review of recent trials published in three general medical journals. BMJ 2003;327:785-9.
40. Reis R, Lösch R, Lago EG. Primary prevention of congenital toxoplsmosis [Prevenção primária da toxoplasmose congênita]. Acta Médica 1999;20:704-20.
41. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
42. Rorman E, Stein Zamir C, Rilkis I, Ben-David H. Congenital toxoplasmosis - prenatal aspects of toxoplasma gondii infection. Reproductive Toxicology 2006;21(4):458-72.
43. Schmidt DR, Hogh B, Andersen O, Fuchs J, Fledelius H, Petersen E. The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999-2002. Archives of Disease in Childhood 2006;91:661-5.
44. Signorell LM, Seitz D, Merkel S, Berger R, Rudin C. Cord blood screening for congenital toxoplasmosis in northwestern Switzerland, 1982-1999. Pediatric Infectious Disease Journal 2006;25:123-8.
45. Thiébaut R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007;369:115-22.
46. Thalib L, Gras L, Romand S, Prusa A, Bessieres MH, Petersen E, et al.Prediction of congenital toxoplasmosis by polymerase chain reaction analysis of amniotic fluid. BJOG: an international journal of obstetrics and gynaecology 2005;112:567-74.
47. Torgerson DJ. Contamination in trials: is cluster randomisation the answer?. BMJ 2001;322:355-7.
48. Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980;66:767-74.
49. Di Mario S, Basevi V, Gagliotti C, Spettoli D, Gori G, D'Amico R, et al.Prenatal education for congenital toxoplasmosis. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006171]
50. Di Mario S, Basevi V, Gagliotti C, Spettoli D, Gori G, D'Amico R, et al.Prenatal education for congenital toxoplasmosis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006171.pub2]